Acromegaly Update

Acromegaly Update

By Ethan WeissScienceLife Sciences
Download on the App Store

Acromegaly Update episodes

  • Acromegaly Update — Monday June 22, 2026
    A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses — while the rare disease industry continues to see a wave of FDA regulatory reversals benefiting gene therapy developers.
    12 min
  • Acromegaly Update — Monday June 15, 2026
    Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.
    7 min
  • Acromegaly Update — Monday June 8, 2026
    A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecast projects orphan drug sales above $400 billion by 2032.
    13 min
  • Acromegaly Update — Monday June 1, 2026
    New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallout from FDA leadership turnover.
    7 min
  • Acromegaly Update — Monday May 25, 2026
    A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, plus rare disease industry news including BioMarin and Intellia, shape the week.
    7 min
  • Acromegaly Update — Monday May 11, 2026
    Acromegaly research this week centered on the long-term pharmacology of established therapies and clinical management updates, while the rare disease industry absorbed significant regulatory and pipeline news.
    7 min
  • Acromegaly Update — Thursday May 7, 2026
    This week's literature brings a long-term safety confirmation for pegvisomant monotherapy, a head-to-head comparison of first-generation somatostatin analogs using a validated composite score, and new evidence linking acromegaly to hepatic steatosis — alongside cost-effectiveness data for pasireotide and updated pituitary tumor pathology tools.
    7 min
  • Acromegaly Update — Monday May 4, 2026
    Two important consensus-level papers from late April 2026 sharpen the standards for acromegaly diagnosis and comorbidity management, incorporating AI-assisted screening, ultrasensitive GH assays, and updated international expert guidance.
    7 min
  • Acromegaly Update — Tuesday April 28, 2026
    This week's acromegaly literature is headlined by a landmark cardiovascular disease review in Endocrine Reviews and a cluster of high-yield JCEM papers covering biomarker-guided therapy, standardized pituitary imaging, patient-reported quality of life, and histological predictors of surgical remission.
    7 min

About Acromegaly Update

From the publisher's feed

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.